THE UNITED STATES PHARMACOPEIAL CONVENTION for THE UNITED STATES PHARMACOPEIAL CONVENTION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S. 1784, H.R. 4191 - Mapping America's Pharmaceutical Supply (MAPS) Act: Provisions regarding supply chain security and resilience and drug shortages. S. 3788 - Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act (CLEAR LABELS) Act: Provisions regarding drug labeling. Issues related to strengthening the resiliency of the U.S. medical supply chain. Issues related to questions for the record (QFRs) for Administration for Strategic Preparedness and Response and Food and Drug Administration nominees.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY J CASEY | — |
Budget/Appropriations BUD
H.R. 5304, S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026: Provisions related to pharmaceutical supply chain resilience. H.R. 4779 - National Security, Department of State, and Related Programs Appropriations Act, 2026: Provisions related to pharmaceutical supply chain resilience.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY J CASEY | — |
Defense DEF
S. 2296 - National Defense Authorization Act for Fiscal Year 2026; H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027: Provisions related to supply chain resilience.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY J CASEY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.